title: MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity.
authors.affiliation: Innate Therapeutics Ltd, PO Box 91806, AMSC, Victoria Street West, Auckland 1142, New Zealand.
authors.forename: Rebecca C
authors.initials: RC
authors.lastname: Girvan
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Knight
authors.forename: Chris J
authors.initials: CJ
authors.lastname: O'Loughlin
authors.forename: Colin M
authors.initials: CM
authors.lastname: Hayman
authors.forename: Ian F
authors.initials: IF
authors.lastname: Hermans
authors.forename: Gill A
authors.initials: GA
authors.lastname: Webster
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage* / Q000302:isolation & purification; D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects / Q000302:isolation & purification; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines; D045142:Cross-Priming; D016207:Cytokines / Q000378:metabolism; D004269:DNA, Bacterial / Q000008:administration & dosage* / Q000302:isolation & purification; D003713:Dendritic Cells / Q000276:immunology; D004705:Endocytosis; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology*; D011425:Propionibacterium acnes / Q000737:chemistry*; D018417:Th1 Cells / Q000276:immunology*; D014611:Vaccination / Q000379:methods
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D016207:Cytokines; D004269:DNA, Bacterial; C000605233:MIS416 vaccine; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D010047:Ovalbumin